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ABSTRACT 
Dual submicromolar trypanocidal-antiplasmodial compounds have been identified by screening and chemical synthesis of 4-aminoquinoline-based 
heterodimeric compounds of three different structural classes. Inhibition of the enzyme trypanothione reductase seems to be involved in the potent 
trypanocidal activity of these heterodimers but likely it is not their main biological target within Trypanosoma brucei. Regarding their antiplasmodial 
activity, the heterodimers seem to share the mode of action of the antimalarial drug chloroquine, which involves inhibition of the haem detoxification 
process. Interestingly, all of these heterodimers display good brain permeabilities, thereby being potentially useful for late stage human African 
trypanosomiasis and cerebral malaria. Future optimization should mainly focus on decreasing cytotoxicity and acetylcholinesterase inhibitory activity. 
1. Introduction
Human African trypanosomiasis (HAT or sleeping sickness), 
one of the 17 so-called neglected tropical diseases, and malaria 
have an enormous health and socioeconomic impact in the 
developing world.
1-3 
Notwithstanding a wide-scale reduction in 
the number of infected people over recent years due to public 
health campaigns, HAT and malaria are still leading causes of 
morbidity and death and of loss of productivity especially in sub-
Saharan Africa.
1,4,5 
Indeed, some 48,000 people die annually from 
HAT,
6
 whereas malaria annually kills more than 600,000 people.
3
 
HAT and malaria are caused by protozoan parasites of the 
genus Trypanosoma and Plasmodium, which are transmitted to 
humans through the bite of blood-feeding infected tsetse flies and 
female Anopheles mosquitoes, respectively. The most common 
form of HAT in humans, accounting for nearly 95% of cases, is 
caused by Trypanosoma brucei gambiense and courses with a 
chronic infection that can last for years. A less common form of 
the disease with a more acute clinical presentation is caused by 
the subspecies Trypanosoma brucei rhodesiense. In the case of 
malaria, five species of Plasmodium may cause the disease, 
Plasmodium falciparum being the most common and deadly. 
HAT begins with a hemolymphatic stage, where the parasite 
multiplies within the blood, lympth and subcutaneous tissue, 
which is characterized by the appearance of nonspecific 
symptoms such as fever and headache. Invasion of the central 
nervous system (CNS) by the parasite after crossing the 
blood‒brain barrier (BBB) leads to the late-stage disease, the 
meningoencephalitic stage, giving rise to severe neurological 
symptoms such as psychiatric, motor and sleep disturbances, loss 
of consciousness, and, without treatment to coma and death. In 
malaria, the parasites initially infect the liver, and then are 
released into the bloodstream. The disease may progress to a 
severe form, where parasites can become sequestered within 
brain capillaries, particularly in children, evolving to cerebral 
malaria and eventually to coma and death.  
 Figure 1. Structures of huprine Y, 1, bis(4-aminoquinoline) homodimer 2 and bis- or mono-(4-aminoquinoline)-based heterodimers of series I-III  
  
Vector control and public health interventions remain the 
main options for prevention, insofar as no licensed vaccine for 
either infection is yet available. Worryingly, currenty available 
chemotherapy against HAT and malaria suffer from serius 
limitations.
1,4,7-9
 Five trypanocidal drugs (pentamidine, suramin, 
melarsoprol, nifurtimox and eflornithine) are used alone or in 
combinations specifically for one or another form or stage of 
HAT, but their relatively high cost, the requirement for long-
lasting parenteral administration, often impracticable in the 
affected poor rural settings, the associated toxicity and 
emergence of parasite resistance, the two latter especially in the 
case of the arsenical melarsoprol,
10
 challenge the widespread, 
safe and efficacious use of these drugs.
11,12
 The emergence of 
resistance is the cause of the loss of effectivenes of chloroquine, 
after decades of being the mainstay for malaria treatment, and it 
starts to challenge also the effectiveness of the current first-line 
treatments based on artemisinin.
1
 
In this scenario, it is of critical importance the enrichment of 
trypanocidal and antimalarial drug development pipelines with 
novel candidates that are devoid of the important flaws of 
existing drugs, i.e. new non toxic and inexpensive chemical 
entities that are effective against resistant parasite strains and are 
brain permeable, so that they may be useful for both disease 
stages in the case of HAT and for cerebral malaria, as well. 
Intensive research efforts involving phenotypic whole-cell 
screening of chemical libraries or newly synthesized 
compounds,
13-16
 identification of novel key biological targets and 
subsequent target-based screening or rational design 
campaigns,
17-21
 development of multitarget-directed ligands,
22-24
 
or drug repurposing programs
1
 are being carried out in the pursuit 
of novel antiprotozoal compounds. 
Because HAT and malaria afflict in a great part the same 
populations, development of compounds endowed with dual 
trypanocidal and antiplasmodial activity can be regarded a 
feasible economic therapeutic strategy.
25
 A number of 4-amino-7-
chloroquinolines and other aminoquinoline derivatives have been 
recently synthesized and found to be active against T. brucei, P. 
falciparum or both of them.
26-29
 This prompted us to assess the 
antiprotozoal activity of huprines, a novel structural class of 
compounds featuring a 4-aminoquinoline moiety, which had been 
initially developed as brain permeable inhibitors of the enzyme 
acetylcholinesterase (AChE). Huprines turned out to be in 
general moderately potent and selective trypanocidal agents, a 
few of them being also active against the chloroquine-resistant 
K1 strain of P. falciparum.
30,31
 The so-called huprine Y (1, Fig. 
1) exhibited the most potent activity against T. brucei (IC50 = 
0.61 µM; IC90 = 2.94 µM) and one of the best selectivity indices 
over rat myoblast L6 cells (SI = 13) but it was essentially devoid 
of antiplasmodial activity.
30
  
Next, we turned our attention to the molecular dimerization of 
huprine Y because this approach had been successfully applied to 
other 4-aminoquinoline derivatives to overcome drug 
resistance.
32-36
 One of the most interesting huprine dimers was 
the novel dodecamethylene-linked bis(4-aminoquinoline) 
compound 2 (Fig. 1), which tripled the potency and selectivity of 
the parent huprine Y against T. brucei but remained inactive 
against P. falciparum.
37
  
The lack of potency of huprine Y and bis-huprines against P. 
falciparum was rather striking because: i) the huprine Y unit 
contains the 4-amino-7-chloroquinoline moiety of chloroquine, 
which is considered to be the pharmocophoric moiety responsible 
for the inhibition of heme dimerization by the antimalarial 
drug
28,38
 and ii) in other bis(4-aminoquinoline) derivatives 
dimerization had been reported to increase antiplasmodial 
potency relative to the 4-aminoquinoline monomeric parent 
compounds due to the doubling of the number of protonatable 
nitrogen atoms, which enabled a more efficient trapping of the 
dimeric compounds in the acidic digestive vacuole of P. 
falciparum, and hence, a more efficient inhibition of heme 
dimerization.
32,35
 In this light, we hypothesized that neither 
huprine Y nor bis-huprines were able to hit the biological target 
of chloroquine and other bis(4-aminoquinoline) derivatives, 
despite their structural similarity. 
To further deepening in the dimerization strategy and 
discovering new hits with dual trypanocidal-antiplasmodial 
activity, herein we report on: i) the screening against cultured 
bloodstream forms of T. brucei and P. falciparum and rat 
myoblast L6 cells of a small in-house library of brain permeable 
4-aminoquinoline-based heterodimeric compounds, belonging to 
three distinct structural classes (series I-III, Fig. 1); ii) the 
synthesis of novel 4-aminoquinoline-based heterodimeric 
compounds of the most interesting series and the evaluation of 
their T. brucei, P. falciparum, rat myoblast L6 cells and human 
AChE inhibitory activities and brain permeability; and iii) the 
identification of the putative biological target in T. brucei and P. 
falciparum of selected hits of the different series and monomeric 
huprine Y by the in vitro evaluation of their inhibitory activity 
against T. brucei trypanothione reductase and β-haematin 
formation. 
 
2. Results and discussion 
2.1. Screening of trypanocidal, antiplasmodial and cytotoxic 
activity of 4-aminoquinoline-based heterodimeric 
compounds of series I-III 
The heterodimers of series I-III (Fig. 1) were recently 
developed by us as inhibitors of the enzyme AChE of potential 
interest for the treatment of Alzheimer’s disease.
39-41
 A high 
AChE inhibitory activity like that displayed by these 
heterodimers (IC50 values in the low nanomolar range) is a 
drawback for antiprotozoal drug development. However, the 
presence of one or two 4-aminoquinoline moieties in the 
structures of these heterodimers and the fact that all of them had 
been found to be brain permeable encouraged us to screen them 
as potential hits of applicability for both stages of HAT and even 
for cerebral malaria, amenable to further optimization of the 
trypanocidal/anticholinesterase activity ratio. 
Heterodimers of series I are a group of 14 racemic or 
enantiopure  bis(4-aminoquinoline) derivatives that contain a unit 
of huprine Y and a unit of the structurally related tacrine 
(heterodimers 3a-f) or 6-chlorotacrine (heterodimers 4a-f), 
connected through linkers of different lenght and nature (hexa- to 
deca-methylene or 4-methyl-4-azaheptamethylene), which are di- 
or tri-protonated at physiological or acidic pH. The antiprotozoal 
activity of heterodimers of series I was assessed in vitro against 
cultured bloodstream forms of T. brucei and the chloroquine-
resistant K1 strain of P. falciparum and their cytotoxicity 
determined against rat skeletal myoblast L6 cells. All of the 
heterodimers of series I are potent trypanocidal agents, exhibiting 
IC50 and IC90 values in the 0.15-0.56 µM and 0.29-0.79 µM 
range, respectively (Table 1). The main structural feature 
influencing distinctly the trypanocidal potency of heterodimers of 
series I is the length of the linker. Indeed, the trypanocidal 
potency seems to increase at increased tether length both in 
heterodimers containing an unsubstituted tacrine moiety 
(heterodimers 3) and in those bearing a 6-chlorotacrine unit 
(heterodimers 4). Thus, the trypanocidal activity peaks in the 
octa- and deca-methylene heterodimers 3d, 4d, 3f and 4f that are 
more than 3-fold more potent than their hexamethylene-linked 
counterparts. In contrast, the presence of a third protonatable 
nitrogen atom within the linker does not seem to have a 
significant influence on trypanocidal potency, heterodimers 3c 
and 4c being roughly equipotent to heptamethylene-linked 
heterodimers 3b and 4b, which have an equivalent tether length.  
Also, the presence or absence of a chlorine atom at the tacrine 
unit does not have much effect on trypanocidal activity, 
heterodimers 3a-f being essentially equipotent to 4a-f. Finally, 
there does not seem to be enantioselectivity in the trypanocidal 
activity of these heterodimers, as enantiopure heterodimers 
(7R,11R)-3b and (7S,11S)-3b and racemic 3b display essentially 
the same potency. Of note, all of the heterodimers of series I are 
more potent than monomeric huprine Y (up to 4-fold when 
considering IC50 values and up to 10-fold when considering IC90 
values). Overall, like in the homodimerization strategy leading to 
bis-huprines such as 2, heterodimerization here results in 
increased trypanocidal potency. 
Strikingly, unlike the parent huprine Y and homodimerization 
leading to bis-huprines, which were inactive against P. 
falciparum, heterodimerization resulted in potent antiplasmodial 
activities, most heterodimers of series I exhibiting IC50 values in 
the submicromolar range (Table 1). Very interestingly, seven of 
these heterodimers were even 2-3-fold more potent than the 
reference compound chloroquine. Some clear structure-activity 
relationship trends were found for this activity in heterodimers of 
series I. Thus, the presence of an unsubstituted tacrine unit and 
increased tether lengths were the structural features leading to 
higher antiplasmodial potencies. The presence of a tertiary amino 
group within the linker only influenced antiplasmodial activity in 
the subseries bearing a chlorosubstituted tacrine unit. Like for 
trypanocidal activity, essentially no enantioselectivity was 
observed for antiplasmodial activity, enantiomeric (7R,11R)-3b 
and (7S,11S)-3b and racemic 3b roughly displaying the same 
potencies. 
With the exceptions of the nonamethylene-linked 
heterodimers 3e and 4e, which displayed a similar or a 5-fold 
lower cytotoxicity relative to the parent huprine Y, the rest of 
heterodimers of series I were more cytotoxic than huprine Y. 
Thus, heterodimers 3e and 4e showed the best selectivity indices 
against T. brucei (SI = 34 and 167, respectively), but only 3e had 
a convenient selectivity index against P. falciparum (SI = 20), 
thereby emerging as the most interesting dual acting 
trypanocidal-antiplasmodial heterodimer of the series. 
Heterodimers of series II are a group of 5 racemic or 
enantiopure compounds that contain a unit of huprine Y or its 9-
ethyl analogue connected through an ethylene or trimethylene 
linker to a piperidine ring substituted at position 4 with a (5,6-
dimethoxyindan-2-yl)methyl group, and are diprotonated at 
physiological or acidic pH. Again, all of the heterodimers of this 
series display potent trypanocidal agents, with IC50 and IC90 
values in the 0.17-0.49 µM and 0.35-1.33 µM range, respectively 
(Table 1), they being up to 4-fold more potent than the parent 
huprine Y when considering IC50 values and up to 8-fold when 
considering IC90 values). The presence of a trimethylene linker 
seemed to have a positive effect on trypanocidal activity, whereas 
no clear trend was found regarding the presence of a methyl or an 
ethyl group at the huprine moiety. Also, there seems not to be 
any enantioselectivity in the trypanocidal action of these 
compounds, as enantiopure (7S,11S)-6a exhibits the same 
potency as the racemic compound. 
 
Table 1 
Trypanocidal, antiplasmodial and cytotoxic activity of 4-aminoquinoline–based heterodimeric compounds 3-10 and reference 
compounds 1 and chloroquine diphosphate
a
 
Compd  X R R’ Y T. brucei 
IC50 µM 
T. brucei 
IC90 µM 
P. falciparum 
IC50 µM 
L6 cells 
IC50 µM 
SITb
b SIPf
b 
3a (CH2)6 H   0.47 ± 0.05 0.66 ± 0.01 2.99 ± 0.85 1.17 ± 0.03 2.5 0.39 
3b (CH2)7 H   0.24 ± 0.04 0.43 ± 0.02 0.47 ± 0.36 <1.0 <4.2 <2.1 
(7R,11R)-3b (CH2)7 H   0.21 ± 0.03 0.42 ± 0.01 0.35 ± 0.15 0.73 ± 0.28 3.5 2.1 
(7S,11S)-3b (CH2)7 H   0.29 ± 0.04 0.49 ± 0.02 0.46 ± 0.19 <1.0 <3.4 <2.2 
3c (CH2)3N(Me)(CH2)3 H   0.32 ± 0.02 0.45 ± 0.01 0.43 ± 0.22 <1.0 <3.1 <2.3 
3d (CH2)8 H   0.15 ± 0.02 0.29 ± 0.01 0.39 ± 0.14 1.11 ± 0.15 7.4 2.8 
3e (CH2)9 H   0.21 ± 0.03 0.45 ± 0.02 0.35 ± 0.06 7.15 ± 0.30 34 20 
3f (CH2)10 H   0.14 ± 0.01 0.48 ± 0.02 nd 1.67 ± 0.04 12 nd 
4a (CH2)6 Cl   0.56 ± 0.03 0.79 ± 0.03 4.40 ± 1.38 1.10 ± 0.01 2.0 0.25 
4b (CH2)7 Cl   0.27 ± 0.06 0.43 ± 0.04 >6.88 <3.0 <11 <0.44 
4c (CH2)3N(Me)(CH2)3 Cl   0.28 ± 0.04 0.40 ± 0.01 0.52 ± 0.13 <1 <3.6 <1.9 
4d (CH2)8 Cl   0.17 ± 0.01 0.46 ± 0.02 >7.14 0.97 ± 0.13 5.7 <0.14 
4e (CH2)9 Cl   0.24 ± 0.04 0.52 ± 0.01 >6.82 40.0 ± 5.1 167 <5.9 
4f (CH2)10 Cl   0.17 ± 0.01 0.49 ± 0.02 2.10 ± 0.72 2.63 ± 0.16 15 1.3 
5a (CH2)2  Me  0.49 ± 0.12 1.18 ± 0.07 >7.01 6.76 ± 0.28 14 <1.0 
5b (CH2)3  Me  0.17 ± 0.01 0.35 ± 0.03 nd 2.06 ± 0.17 12 nd 
6a (CH2)2  Et  0.29 ± 0.03 0.70 ± 0.04 >7.14 3.55 ± 0.17 12 <0.50 
(7S,11S)-6a (CH2)2  Et  0.29 ± 0.02 0.72 ± 0.03 >7.05 6.29 ± 0.58 22 <0.89 
(7S,11S)-6b (CH2)3  Et  0.26 ± 0.03 1.33 ± 0.10 0.81 ± 0.20 2.15 ± 0.06 8.3 2.7 
7a (CH2)2 H  O 0.41 ± 0.03 0.88 ± 0.07 >8.15 <3.0 <7.3 <0.37 
7b (CH2)3 H  O 0.28 ± 0.02 0.62 ± 0.04 nd <1.0 <3.6 nd 
8a (CH2)2 Cl  O 0.30 ± 0.03 0.68 ± 0.04 4.86 ± 3.30 <3.0 <10 <0.62 
8b (CH2)3 Cl  O 0.12 ± 0.01 0.17 ± 0.03 0.36 ± 0.07 0.57 ± 0.19 4.7 1.6 
9a (CH2)2 H  H,H 0.38 ± 0.04 0.79 ± 0.01 2.60 ± 1.91 <3.0 <7.9 <1.2 
9b (CH2)3 H  H,H 0.27 ± 0.03 0.66 ± 0.03 0.83 ± 0.44 <3.0 <11 <3.6 
10a (CH2)2 Cl  H,H 0.97 ± 0.11 2.39 ± 0.08 >7.72 2.42 ± 0.20 2.5 <0.31 
10b (CH2)3 Cl  H,H 0.34 ± 0.07 0.66 ± 0.04 6.04 ± 5.94 <3.0 <8.8 <0.5 
1c     0.61 ± 0.03 2.94 ± 0.20 >10 7.80 ± 0.47 13 <0.78 
chloroquine       0.93 ± 0.44    
a In vitro activity against bloodstream form of T. brucei (pH 7.4), P. falciparum (strain K1), and rat myoblast L6 cells expressed at the concentration that 
inhibited growth by 50% (IC50) and 90% (IC90, for trypanocidal activity). Data are the mean of triplicate experiments ± SEM. 
b SI: Selectivity index is the ratio of cytotoxic to trypanocidal (SITb) or antiplasmodial (SIPf) IC50 values. 
c Activity values of reference compound 1 taken from ref. 30.
In sharp contrast with series I, most heterodimers of series II 
were essentially inactive against P. falciparum, with the sole 
exception of 6b (IC50 = 0.81 µM, Table 1), which is roughly 
equipotent to the reference antimalarial drug chloroquine. 
All of the heterodimers of series II turned out to be slightly 
more cytotoxic than the parent huprine Y. However, their 
superior trypanocidal potencies lead to similar or even better 
selectivity indices against T. brucei than that of huprine Y (in 
almost all cases over 10). 
Heterodimers of series III form a group of 8 compounds that 
combine the 4-aminoquinoline unit of tacrine or 6-chlorotacrine 
with the 4-[(5,6-dimethoxyindan-2-yl)methyl]piperidine group 
that was also present in series II or with the indanone derivative 
thereof (Fig. 1). Like the other series, all of these heterodimers 
are submicromolar trypanocidal agents (IC50 = 0.12-0.97 µM, 
IC90 = 0.17-2.39 µM, Table 1), most potent than huprine Y. The 
presence of an indanone system and a trimethylene linker are the 
structural features that lead to higher trypanocidal potencies. As 
for the influence of the presence of an unsubstituted or a 6-
chloro-substituted tacrine unit, the former seems to be optimal for 
the indane derivatives and the latter for the indanone analogues. 
Most heterodimers of series III are submicromolar or low 
micromolar antiplasmodial compounds, one of them, 8b, being 3-
fold more potent than chloroquine. Like for the trypanocidal 
activity, in general the antiplasmodial potency of these 
heterodimers increased with the presence of an indanone system, 
a trimethylene linker and a tacrine or a 6-chlorotacrine unit for 
the indane or the indanone derivatives, respectively. 
An important flaw of heterodimers of series III is their 
cytotoxicity, in general superior to that of huprine Y and the 
other series of heterodimers, which results in poor selectivity 
indices against both T. brucei and P. falciparum. 
Overall, all of the 27 screened 4-aminoquinoline-based 
heterodimers turned out to be more potent trypanocidal agents 
than huprine Y and 10 of them (most belonging to series I) also 
exhibited more potent antiplasmodial activity than the 
antimalarial drug chloroquine, even though most heterodimers 
have inadequate selectivity indices for trypanocidal and 
antiplasmodial over cytotoxic activities. Likely the most 
interesting hit is heterodimer 3e (series I), with a balanced dual 
trypanocidal (IC50 = 0.21 µM) and antiplasmodial (IC50 = 0.35 
µM) activity and selectivity indices of 34 and 20 for these 
activities over L6 cell cytotoxicity. 
 
2.2. Synthesis of novel 4-aminoquinoline-based 
heterodimeric compounds  
Taking into account: i) the most favourable dual  
trypanocidal/antiplasmodial profile of heterodimers of series I; ii) 
their easier and, hence, less expensive synthesis relative to 
heterodimers of series II and III; iii) and the trend towards 
increased trypanocidal and antiplasmodial potencies at increased 
tether lengths, we envisioned the synthesis and biological 
profiling of the upper dodecamethylene-linked homologues of 
series I 3g and 4g (Scheme 1). On the other hand, because 
removal of the chlorine atom at position 3 of the huprine moiety 
is known to decrease AChE inhibitory activity,
42
 we also 
undertook the synthesis and evaluation of the deca- and dodeca-
methylene-linked heterodimers 16f-g and 17f-g bearing a 3-
unsubstituted huprine moiety (Scheme 1). 
The synthesis of the novel heterodimers of series I involved 
an initial alkylation of tacrine, 11, or 6-chlorotacrine, 12, with 
1,10-dibromodecane or 1,12-dibromododecane in the presence of 
KOH in DMSO, which afforded the known 10-
bromodecyltacrines 13f
39
 and 14f
39
 and the novel 12-
bromododecyltacrines 13g and 14g in moderate yields (30-39%) 
(Scheme 1). Subsequent alkylation of huprine Y, 1, or its 3-
unsubstituted derivative 15 with the ω-haloalkyltacrines 13f-g or 
14f-g under similar conditions at rt for 4 days, afforded the novel 
heterodimers 3g, 4g, 16f-g and 17f-g in moderate to good yields 
(45-88%) after silica gel column chromatography purification of 
the reaction crudes. 
The novel heterodimers were converted into the corresponding 
dihydrochlorides for their chemical characterization (melting 
point, IR, 
1
H and 
13
C NMR, HRMS and elemental analysis) and 
biological profiling. 
 
2.3. Biological profiling of the novel 4-aminoquinoline-
based heterodimeric compounds 
The putative dual trypanocidal/antiplasmodial and cytotoxic 
activities of the novel heterodimers 3g, 4g, 16f-g and 17f-g were 
evaluated in vitro against cultured bloodstream forms of T. 
brucei, the chloroquine-resistant K1 strain of P. falciparum, and 
rat skeletal myoblast L6 cells, respectively. Additionally, their 
inhibitory activity against human recombinant AChE was 
evaluated in vitro by the method of Ellman et al.
43
 and their brain 
permeation assessed through the well-established parallel 
artificial membrane permeability assay (PAMPA-BBB).
44 
 
Scheme 1. Reagents and conditions: (a) 11 or 12, KOH, 
DMSO, 2 h; then, 1,10-dibromodecane or 1,12-
dibromododecane (1.2 eq), DMSO, rt, overnight; (b) 1 or 15, 
KOH, DMSO, 2 h; then, 13f-g or 14f-g (1.2 eq), DMSO, rt, 4 
days. 
 
All of the novel heterodimers turned out to be more potent 
trypanocidal agents than the parent huprine (up to 3- and 10-fold 
when considering IC50 or IC90 values, respectively) (Table 2). 
Elongation of the tether chain from 10 methylenes in 3f and 4f to 
12 methylenes in the novel heterodimers 3g and 4g resulted in a 
slightly decreased potency, so that the octa- and deca-methylene 
chains remained the most adequate linkers for trypanocidal 
activity of huprine Y-based heterodimers of series I, as found in 
the initial screening campaign. Substitution of the huprine Y unit 
of heterodimers of series I by a 3-unsubstituted huprine moiety 
led in general to slightly increased trypanocidal potencies, 
especially if IC90 values are taken into account. Indeed, the novel 
heterodimer 16g exhibited the lowest IC90 value (0.28 µM) 
among all the heterodimers of series I. 
Unlike most previously screened heterodimers of series I, the 
novel heterodimers 3g, 4g, 16f-g and 17f-g were found to be 
essentially inactive or only moderately potent antiplasmodial 
compounds, displaying one-digit micromolar activities in the best 
cases (Table 2). Thus, homologation of the tether chain to a 
dodecamethylene linker and removal of the chlorine atom at 
position 3 of the huprine unit are detrimental for antiplasmodial 
activity. 
Similarly to most of the screened heterodimers of series I, the 
novel analogues had inadequate selectivity indices for both T. 
brucei and P. falciparum over rat L6 cells. 
To complete the biological profiling of the novel 
heterodimers, their brain permeation and human AChE inhibitory 
activities were assessed.  
 
 
Table 2 
Trypanocidal, antiplasmodial, cytotoxic, and anticholinesterase activity and BBB permeabilities of the novel 4-aminoquinoline–
based heterodimeric compounds 3g, 4g, 16f-g, and 17f-g and reference compounds 1 and chloroquine diphosphate
a
 
Compd X R R” T. brucei 
IC50 µM 
T. brucei 
IC90 µM 
P. falciparum 
IC50 µM 
L6 cells 
IC50 µM 
SITb
b 
 
SIPf
b
 hAChE 
IC50 (nM) 
Pe (10–6 cm s–6)c 
(Prediction) 
3g (CH2)12 H Cl 0.35 ± 0.01 0.52 ± 0.01 >6.9 1.04 ± 0.02 3.0 <0.15 1.92 ± 0.40 10.8 ± 1.0 (CNS+) 
4g (CH2)12 Cl Cl 0.59 ± 0.05 0.77 ± 0.01 >6.6 5.58 ± 0.53 9.5 <0.85 3.46 ± 0.56 16.8 ± 0.3 (CNS+) 
16f (CH2)10 H H 0.24 ± 0.01 0.31 ± 0.04 3.50 ± 2.29 <1 <4.2 <0.29 6.46 ± 1.43 6.3 ± 1.1 (CNS+) 
16g (CH2)12 H H 0.21 ± 0.00 0.28 ± 0.01 >7.3 <1 <4.8 <0.14 10.1 ± 1.19 7.3 ± 0.7 (CNS+) 
17f (CH2)10 Cl H 0.34 ± 0.02 0.43 ± 0.01 4.36 ± 2.82 1.11 ± 0.04 3.3 0.25 1.48 ± 0.24 17.2 ± 1.6 (CNS+) 
17g (CH2)12 Cl H 0.55 ± 0.01 0.75 ± 0.01 >6.9 2.74 ± 0.29 5.0 <0.40 3.66 ± 0.33 11.0 ± 1.0 (CNS+) 
1d    0.61 ± 0.03 2.94 ± 0.20 >10 7.80 ± 0.47 13 <0.78 0.61 ± 0.03e 23.8 ± 2.7 (CNS+)f 
chloroquine      0.93 ± 0.44      
a In vitro activity against bloodstream form of T. brucei (pH 7.4), P. falciparum (strain K1), and rat myoblast L6 cells expressed at the concentration that 
inhibited growth by 50% (IC50) and 90% (IC90, for trypanocidal activity) and in vitro activity against human recombinant AChE expressed at the concentration 
that inhibited enzyme activity by 50% (IC50). Data are the mean of triplicate experiments ± SEM. 
b SI: Selectivity index is the ratio of cytotoxic to trypanocidal (SITb) or antiplasmodial (SIPf) IC50 values. 
c Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ± SD of three independent experiments. 
d Antiprotozoal and cytotoxic activity values of reference compound 1 taken from ref. 30. 
e Taken from ref. 40. 
f Taken from ref. 45.
 
Brain permeation of the novel heterodimers was determined in 
vitro through the widely used PAMPA-BBB assay,
44
 using a lipid 
extract of porcine brain as an artificial membrane model of BBB. 
The heterodimerization strategy, as it was also found for 
homodimerization,
37
 results in dibasic bis(4-aminoquinoline) 
derivatives that will be mostly diprotonated under the assay 
conditions, which explains their lower permeabilities relative to 
the parent monobasic huprine Y (Table 2). However, all the 
heterodimers had permeabilities well above the threshold 
established for high BBB permeation (Pe (10
6
 cm s
1
) > 5.1, 
CNS+, Table 2). As expected, elongation of the linker from 10 to 
12 methylenes and the presence of a chlorine substituent at the 
huprine moiety lead to increased lipophilicity, and, hence, 
increased brain permeability. 
As expected, replacement of the 3-chlorosubstituted huprine Y 
unit in these heterodimers by a 3-unsubstituted huprine moiety 
results in general in a reduced inhibitory activity against human 
recombinant AChE. However, the reduction of this activity was 
very modest, so that the novel heterodimers 16f-g and 17f-g 
remain very active anticholinesterasic compounds, as it is also 
the case for 3g and 4g (Table 2). 
Thus, extension of series I with the novel heterodimers has 
resulted in the identification of two of the most potent 
trypanocidal compounds of the series, 16f and 16g, the latter 
displaying also significant antiplasmodial activity. Reduction of 
their cytotoxicity and AChE inhibitory activities will need to be 
addressed in future development of this structural class. 
 
2.4. Determination of the trypanocidal and antiplasmodial 
mode of action of 4-aminoquinoline-based heterodimeric 
compounds of series I-III 
Identification of the biological target responsible or, at least, 
in part involved in the trypanocidal and antiplasmodial activity of 
the heterodimers of series I-III might enable further optimization 
of the initial hits through target-based screening or by structure-
based rational design of novel analogues, when 3D structures of 
the biological target are available. 
 
2.4 .1 .  Trypanothione reductase  inhibi tory act iv i ty  
Trypanothione reductase (TryR) is a NADPH-dependent 
disulfide oxidoreductase enzyme that is involved in the 
protection of trypanosomatid parasites from oxidative damage. 
Because it is unique and essential to these parasites, TryR 
constitutes a valuable target for trypanocidal drug discovery 
programs.
46,47
 
A number of quinoline (ref 20) or aminoacridine derivatives 
have been reported to be inhibitors of TryR.
20,46,48,49
 In these 
compounds the presence of a protonatable nitrogen atom seems 
to be crucial for the TryR inhibitory activity because it mimics 
the positively charged substrate, trypanothione disulfide. 
Interestingly, it has been reported that dimerization of several 
classes of compounds with known TryR inhibitory activity leads 
to increased potency,
50-52
 which might be related to the presence 
of two interacting binding sites in the large active site of TryR.
49
 
These precedents prompted us to determine whether TryR was 
a biological target for aminoquinoline-based heterodimers of 
series I-III. The TryR inhibitory activity of selected compounds 
of these series, namely heterodimers 3d, 5b and 8b, as well as the 
parent huprine Y, 1, was determined through a described 
methodology based on the colorimetric reduction of 5,5'-
dithiobis(2-nitrobenzoic) acid (DTNB) by dithiol trypanothione 
(T[SH]2), the product of the reaction catalyzed by TryR.
53,54
 
The four tested compounds exhibited submicromolar to low 
micromolar IC50 values for TryR inhibition (Table 3). The most 
potent compound turned out to be 3d (series I) which was 6-8-
fold more potent than the parent huprine and the heterodimers of 
the other series. Thus, as previously reported for other structural 
classes, dimerization of a 4-aminoquinoline motif in 3d relative 
to huprine Y resulted in increased TryR inhibitory activity. 
 
Table 3 
Inhibitory activity of selected 4-aminoquinoline-based 
heterodimeric compounds and reference compounds 1, 
tetracycline hydrochloride and chloroquine diphosphate 
against T. brucei trypanothione reductase and β-haematin 
formation
a
 
Compd  Tb TryRb 
IC50 µM 
BHIA50
c  
3d 0.87 ± 0.10 0.19 ± 0.02 
5b 4.88 ± 0.44 0.42 ± 0.06 
8b 7.39 ± 0.43 0.54 ± 0.08 
1 5.00 ± 0.31 >4 
tetracycline  >4 
chloroquine  0.14 ± 0.05 
a Values are expressed as the mean ± SD of three independent experiments. 
b In vitro activity against recombinant T. brucei TryR expressed at the 
concentration that inhibited enzyme activity by 50% (IC50). 
b β-Haematin inhibitory activity in equivalents of drug relative to haemin 
causing 50% inhibition. 
 
Of note, no correlation was found between the trypanocidal 
and TryR inhibitory activities of these compounds. Indeed, all the 
tested compounds displayed more potent trypanocidal than TryR 
inhibitory activity (6-62-fold). These results might suggest that 
either TryR is not the sole target of these compounds or that they 
might be selectively concentrated into the cell or metabolically 
activated, as suggested for other trypanocidal compounds.
55
 
 
2.4 .2 .  Inhibi t ion  of  β -haematin formation  
The 4-amino-7-chloroquinoline unit present in chloroquine 
and other antimalarial compounds is the pharmacophoric moiety 
responsible for the inhibition of dimerization and crystallization 
of free haem, generated during the digestion of hemoglobin in the 
host erythrocytes, into nontoxic insoluble haemozoin, which 
results in increased levels of toxic haem and, hence, in parasite 
death.
28,56
 
Huprine Y, 1, and bis-huprine 2 contain the 4-amino-7-
chloroquinoline moiety but they are inactive against P. 
falciparum.
30,37
 Surprisingly, many heterodimers of series I-III, 
which in most cases also feature one or two 4-amino-7-
chloroquinoline motifs, have been found to be quite potent 
antiplasmodial compounds (Tables 1 and 2). In the light of these 
results, we assessed whether the antiplasmodial activity of these 
heterodimers relied on the same mechanism of action of 
chloroquine, by determining the inhibition of the formation of β-
haematin, which is identical to haemozoin. Thus, the inhibitiory 
activity against β-haematin formation of heterodimers 3d, 5b and 
8b was evaluated following a described procedure,
57,58
 and 
expressed as the 50% inhibitory concentration for β-haematin 
inhibition in equivalents of the tested compound relative to 
haemin (BHIA50). The parent huprine Y and tetracycline were 
also evaluated as negative controls and chloroquine was used as a 
positive control.  All the tested heterodimers inhibited β-
haematin formation comparably to that seen with chloroquine, 
whereas huprine Y and tetracycline showed no inhibition (Table 
3). Particularly, heterodimer 3d (series I) was equipotent to 
chloroquine as inhibitor of β-haematin formation (Table 3) and 
heterodimers 5b and 8b turned out to be slightly less potent (3- 
and 4-fold). Because the β-haematin formation inhibitory 
activities of these heterodimers correlate well with their 
antiplasmodial activities, it might be suggested that inhibition of 
β-haematin formation is likely an important mechanim by which 
they inhibit the growth of malaria parasites. 
 
3. Conclusion 
We have identified a number of dual submicromolar 
trypanocidal-antiplasmodial compounds by phenotypic screening 
against bloodstream forms of T. brucei and the multidrug-
resistant strain K1 of P. falciparum of a small library of 27 brain 
permeable 4-aminoquinoline-based heterodimeric compounds 
belonging to three distinct structural classes. Indeed, all of the 
tested compounds displayed submicromolar IC50 values, and the 
vast majority also submicromolar IC90 values against T. brucei, 
they being more potent trypanocidal agents than the parent 
huprine Y. One third of them exhibited also submicromolar IC50 
values against P. falciparum and increased potency relative to the 
reference antimalarial compound chloroquine. In a further 
extension of the most promising structural class (series I) to 
expand the structure-activity relationships studies and to decrease 
the AChE inhibitory activity, which was present in all the 
screened compounds, 6 novel heterodimers were synthesized and 
biologically evaluated. All of the novel compounds kept high 
trypanocidal potency and good BBB permeability and a few of 
them also moderately potent antiplasmodial activity, but also 
AChE inhibitory potency and not too adequate selectivity 
indices. 
Mechanistic studies have shown that the high trypanocidal 
activity of these heterodimers can be only partly ascribed to 
inhibition of the enzyme TryR, whereas their antiplasmodial 
activity seems to arise from an inhibition of the haem 
detoxification process, like in the antimalarial drug chloroquine. 
Heterodimer 3e (series I) emerges as an interesting hit 
featuring  balanced dual trypanocidal (IC50 = 0.21 µM) and 
antiplasmodial (IC50 = 0.35 µM) activity and selectivity indices 
of 34 and 20 for these activities over rat L6 cell cytotoxicity. 
Further optimization should address an improvement of the 
selectivity indices and a reduction of AChE inhibitory activities 
of these heterodimers. 
 
4. Experimental 
4.1. Chemistry 
Melting points were determined in open capillary tubes with a 
MFB 595010M Gallenkamp melting point apparatus. 400 MHz 
1
H / 100.6 MHz 
13
C NMR spectra were recorded on a Varian 
Mercury 400 spectrometer at the Centres Científics i Tecnològics 
of the University of Barcelona (CCiTUB). The chemical shifts 
are reported in ppm (δ scale) and coupling constants are reported 
in Hertz (Hz). The syn (anti) notation of the protons at position 
13 of the huprine moiety of the heterodimers means that the 
corresponding proton at position 13 is on the same (different) 
side of the quinoline moiety with respect to the cyclohexene ring. 
IR spectra were run on a Perkin-Elmer Spectrum RX I 
spectrophotometer, using KBr pellets. Absorption values are 
expressed as wave-numbers (cm
1
); only significant absorption 
bands are given. Column chromatography was performed on 
silica gel 60 AC.C (4060 μM, SDS, ref 2000027). Thin-layer 
chromatography was performed with aluminum-backed sheets 
with silica gel 60 F254 (Merck, ref 1.05554), and spots were 
visualized with UV light and 1% aqueous solution of KMnO4. 
Elemental analyses and high resolution mass spectra were carried 
out at the Mycroanalysis Service of the IIQAB (CSIC, Barcelona, 
Spain) with a Carlo Erba 1106 analyzer, and at the CCiTUB with 
a LC/MSD TOF Agilent Technologies spectrometer, 
respectively. The analytical samples of all of the heterodimers 
that were subjected to pharmacological evaluation were dried at 
65 ºC / 2 Torr at least for 2 days (standard conditions) and 
possess a purity 95% as evidenced by their elemental analyses. 
4.1 .1 .  9-(12 -Bromododecyl )amino -1 ,2 ,3 ,4 -
tetrahydroacrid ine (13g )  
A suspension of tacrine, 11 (3.00 g, 15.2 mmol, 1 eq), and 
finely powdered KOH (85% purity reagent, 1.60 g, 24.3 mmol, 
1.6 eq) in anhydrous DMSO (37 mL) was stirred, heating every 
10 min approximately with a heat gun for 1 h and at rt for an 
additional hour. This mixture was added dropwise during 1.5 h to 
a solution of 1,12-dibromododecane (5.98 g, 18.2 mmol, 1.2 eq) 
in anhydrous DMSO (20 mL), containing 4 Å molecular sieves. 
The reaction mixture was stirred at rt overnight, diluted with 10N 
NaOH (150 mL) and H2O (200 mL) and extracted with EtOAc 
(3200 mL). The combined organic extracts were washed with 
H2O (2200 mL), dried over anhydrous Na2SO4, and evaporated 
at reduced pressure to give a yellow oil (8.02 g), which was 
purified by column chromatography (40–60 µm silica gel, 
CH2Cl2/50% aq. NH4OH 100:0.2), to afford bromoalkyl 
derivative 13g (2.65 g, 40% yield); Rf 0.27 (CH2Cl2/MeOH/50% 
aq. NH4OH 9:1:0.05). 
A solution of 13g (106 mg, 0.24 mmol) in MeOH (10 mL) 
was filtered through a 0.2 µm NYL filter and treated with 45% 
aq. HBr (0.50 mL, 4.14 mmol, 17 eq). The resulting solution was 
evaporated at reduced pressure and the solid was taken in MeOH 
(0.1 mL) and precipitated upon addition of AcOEt (1.2 mL). The 
precipitated solid was separated and washed with pentane (32 
mL) to give, after drying under standard conditions, 13g·HBr (49 
mg) as a yellowish solid: mp 131–133 ºC; IR (KBr) ν 3500–2500 
(max at 3255, 3044, 3004, 2915, 2846 and 2793, N
+
–H, N–H, 
and C–H st), 1629, 1588, 1573 and 1517 (Ar–C–C, Ar–C–N st) 
cm
–1
; 
1
H NMR (400 MHz, CD3OD) δ 1.29–1.47 (complex signal, 
16H, 3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2, 8’-H2, 9’-H2, 10’-H2), 
1.79–1.87 (complex signal, 4H, 2’-H2, 11’-H2), 1.94–2.01 
(complex signal, 4H, 2-H2, 3-H2), 2.71 (m, 2H, 1-H2), 3.02 (m, 
2H, 4-H2), 3.43 (t, J = 6.6 Hz, 2H, 12’-H2), 3.96 (t, J = 7.2 Hz, 
2H, 1’-H2), 4.85 (s, NH, NH
+
), 7.59 (ddd, J = 8.6 Hz, J’ = 7.0 Hz, 
J” = 1.6 Hz, 1H, 7-H), 7.75 (dd, J = 8.4 Hz, J’ = 0.8 Hz, 1H, 5-
H), 7.86 (ddd, J = 8.3 Hz, J’ = 6.9 Hz, J” = 1.3 Hz, 1H, 6-H), 
8.40 (d, J = 8.4 Hz, 1H, 8-H); 
13
C NMR (100.6 MHz, CD3OD) δ 
21.8 (CH2, C3), 23.0 (CH2, C2), 24.9 (CH2, C1), 27.7 (CH2 C3’), 
29.1 (CH2, C10’), 29.3 (CH2, C4), 29.8 (CH2), 30.2 (CH2), 30.51 
(3 CH2) and 30.54 (CH2), (C4’, C5’, C6’, C7’, C8’, C9’), 31.5 
(CH2) and 34.0 (CH2) (C2’, C11’), 34.5 (CH2, C8’), 49.2 (2 CH2, 
C1’, C12’), 112.8 (C) and 117.0 (C) (C8a, C9a) 120.1 (CH, C5), 
126.3 (CH, C7), 126.5 (CH, C8), 134.1 (C, C6), 139.7 (C, C10a), 
151.6 (C, C4a), 158.0 (C, C9); HRMS (ESI), calcd for 
[C25H37BrN2 + H
 +
] 445.2213, found 445.2212. 
4.1 .2 .  9-(12 -Bromododecyl )amino -6 -chloro-1 ,2 ,3 ,4 -
tetrahydroacrid ine (14g)  
It was prepared as described for 13g. Starting from 6-
chlorotacrine, 12 (2.00 g, 8.60 mmol, 1 eq), and a solution of 
1,12-dibromododecane (3.38 g, 10.3 mmol, 1.2 eq) in anhydrous 
DMSO (20 mL), a brown oil (4.70 g) was obtained and subjected 
to column chromatography purification (40–60 µm silica gel, 
CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient elution). On 
elution with CH2Cl2/MeOH/50% aq. NH4OH 100:0:0.2, 
bromoalkyl derivative 14g (546 mg) was isolated. On elution 
with CH2Cl2/MeOH/50% aq. NH4OH 100:0:0.2 to 90:10:0.2, a 
mixture of 14g and starting 12 (2.60 g) was obtained. Column 
chromatography purification of this mixture (40–60 µm silica 
gel, CH2Cl2/50% aq. NH4OH 100:0.2) afforded more 14g (691 
mg, 30% total yield); Rf 0.46 (CH2Cl2/MeOH/50% aq. NH4OH 
9:1:0.05). 
A solution of 14g (100 mg, 0.21 mmol) in MeOH (18 mL) 
was filtered through a 0.2 μm NYL filter and treated with 45% 
aq. HBr (0.5 mL, 4.14 mmol, 20 eq). The resulting solution was 
evaporated at reduced pressure and the solid was washed with 
pentane (32 mL) to give, after drying under standard conditions, 
14g·HBr (87 mg) as a beige solid: mp 122–124 ºC; IR (KBr) ν 
3500–2500 (max at 3241, 3134, 3044, 2921, 2850 and 2791 N
+
–
H, N–H, and C–H st), 1630, 1620, 1588, 1572, 1546 and 1521, 
(Ar–C–C, Ar–C–N st) cm
–1
; 
1
H NMR (400 MHz, CD3OD) δ 
1.29–1.43 (complex signal, 16H, 3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-
H2, 8’-H2, 9’-H2, 10’-H2), 1.78–1.87 (complex signal, 4H, 2’-H2, 
11’-H2), 1.96–1.97 (complex signal, 4H, 2-H2, 3-H2), 2.68 (m, 
2H, 1-H2), 3.00 (m, 2H, 4-H2), 3.43 (t, J = 6.6 Hz, 2H, 12’-H2), 
3.94 (t, J = 7.6 Hz, 2H, 1’-H2), 4.85 (s, NH, NH
+
), 7.56 (dd, J = 
9.2 Hz, J’ = 2.0 Hz, 1H, 7-H), 7.77 (d, J = 2 Hz, 1H, 5-H), 8.39 
(d, J = 9.2 Hz, 1H, 8-H); 
13
C NMR (100.6 MHz, CD3OD) δ 21.8 
(CH2, C3), 22.9 (CH2, C2), 24.7 (CH2, C1), 27.7 (CH2, C3’), 29.1 
(CH2, C10’), 29.3 (CH2, C4), 29.8 (CH2), 30.2 (CH2) and 30.5 (4 
CH2) (C4’, C5’, C6’, C7’, C8’, C9’), 31.3 (CH2) and 34.0 (CH2) 
(C2’, C11’), 34.4 (CH2, C8’), 49.2 (2 CH2, C1’, C12’), 113.3 (C) 
and 115.4 (C) (C8a, C9a), 119.1 (CH, C5), 126.8 (CH, C7), 
128.8 (CH, C8), 140.1 (C, C6), 140.5 (C, C10a), 152.1 (C, C4a), 
157.9 (C, C9); HRMS (ESI), calcd for [C25H36BrClN2 + H
 +
] 
479.1823, found 479.1830. 
4.1 .3 .  3-Chloro-6 ,7 ,10 ,11 -tetrahydro -9-methyl -12-
12-[(1 ,2 ,3 ,4 -te trahydroacrid in -9 -
yl )amino]dodecylamino -7 ,11 -
methanocyclooc ta[ b ]quinol ine (3g)  
A mixture of finely powdered KOH (85% purity reagent, 209 
mg, 3.16 mmol, 3 eq), huprine 1 (300 mg, 1.05 mmol, 1 eq), 4 Å 
molecular sieves (approximately 690 mg) in dry DMSO (4 mL) 
was thoroughly stirred for 1 h heating with a heatgun every 10 
min and for one additional hour at rt. The resulting mixture was 
added dropwise during 1 h to a mixture of bromoalkyltacrine 13g 
(562 mg, 1.26 mmol, 1.2 eq) in dry DMSO (6 mL). The reaction 
mixture was vigorously stirred at rt for 4 days, diluted with 10 N 
NaOH (150 mL), H2O (200 mL), and extracted with AcOEt 
(3200 mL). The combined organic extracts were washed with 
1N NaOH (3200 mL), dried with anhydrous Na2SO4 and 
evaporated at reduced pressure to give a brown oily residue (820 
mg), which was subjected to column chromatography (4060 
mesh silica gel, CH2Cl2/50% aqueous NH4OH 100:0.2), to afford 
heterodimer 3g (507 mg, 71% yield) as a yellow oil; Rf 0.48 
(CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of 3g (507 mg, 0.78 mmol) in CH2Cl2 (26 mL) was 
filtered through a 0.2 m NYL filter, and treated with an excess 
of a methanolic solution of HCl (1.45 N, 4.9 mL, 7.10 mmol) and 
the resulting solution was concentrated in vacuo to dryness. The 
solid was taken in MeOH (1.5 mL) and precipitated upon 
addition of AcOEt (12 mL). The precipitated solid was separated, 
washed with pentane (32), and dried under standard conditions, 
to give 3g·2HCl (362 mg) as a yellow solid: mp: 165-168 ºC; IR 
(KBr) ν 3500–2500 (max at 3380, 3234, 3108, 3048, 3007, 2923, 
2850, 2788 and 2651, N
+
–H, N–H, and C–H st), 1632, 1583 and 
1521 (Ar–C–C, Ar–C–N st) cm
–1
; 
1
H NMR (400 MHz, CD3OD) 
δ 1.27–1.46 (complex signal, 16H, 3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-
H2, 8’-H2, 9’-H2, 10’-H2), 1.58 (s, 3H, 9-CH3), 1.79–1.95 
(complex signal, 10H, 10-Hendo, 13-Hsyn, 2’-H2, 11’-H2, 2”-H2, 3”-
H2), 2.08 (d, J = 12.4 Hz, 1H, 13-Hanti), 2.55 (br dd, J = 17.2 Hz, 
J’ = 3.6 Hz, 1H, 10-Hexo), 2.70 (m, 2H, 1”-H2), 2.77 (br m, 1H, 7-
H), 2.88 (d, J = 17.6 Hz, 1H, 6-Hendo), 3.02 (m, 2H, 4”-H2), 3.20 
(dd, J = 18.0 Hz, J’ = 5.2 Hz, 1H, 6-Hexo), 3.46 (br m, 1H, 11-H), 
3.96 (m, 4H, 1’-H2, 12’-H2), 4.85 (s, NH, NH
+
), 5.58 (br d, J = 
5.2 Hz, 1H, 8-H), 7.54 (d, J = 9.2 Hz, 1H, 2-H), 7.56 (t, J = 7.6 
Hz, 1 H, 7”-H), 7.80 (s, 1H, 4-H), superimposed in part 7.77 (d, J 
= 7.2 Hz, 1H, 5”-H), superimposed in part 7.83 (dd, J = 14.8 Hz, 
J’ = 8.0 Hz, 1H, 6”-H), 8.38 (dd, J = 8.8 Hz, J’ = 2.4 Hz, 2 H, 1-
H, 8’’-H); 
13
C NMR (100.6 MHz, CD3OD) δ 21.8 (CH2, C3”), 
23.0 (CH2, C2”), 23.5 (CH3, 9-CH3), 24.9 (CH2, C1”), 27.3 (CH, 
C11), 27.68 (CH), 27.77 (CH2) and 27.81 (CH) (C7, C3’, C10’), 
29.3 (2 CH2) (C13, C4”), 30.2 (CH2), 30.3 (CH2) and 30.6 (4 
CH2) (C4’, C5’, C6’, C7’, C8’, C9’), 31.2 (CH2) and 31.5 (CH2) 
(C2’, C11’), 36.0 (CH2) and 36.1 (CH2) (C6, C10), 49.1 (CH2) 
and 49.6 (CH2) (C1’, C12’), 112.8 (C), 115.6 (C), 117.0 (C) and 
117.6 (C) (C11a, C12a, C8a”, C9a”), 119.1 (CH) and 120.1 (CH) 
(C4, C5”), 125.1 (CH, C8), 126.3 (CH, C7”), 126.5 (CH, C8”), 
126.6 (CH, C2), 129.4 (CH, C1), 134.1 (CH, C6”), 134.5 (C, 
C9), 139.7 (C), 140.2 (C) and 141.0 (C) (C3, C4a, C10a”), 151.2 
(C) and 151.6 (C) (C5a, C4a”), 156.8 (C), 158.0 (C) (C12, C9”); 
HRMS (ESI), calcd for [C42H54
35
ClN4 + H
 +
] 649.4032, found 
649.4019; Anal. calcd. for C42H53ClN4·2HCl·1.5H2O: C, 67.32; 
H, 7.80; N, 7.48; Cl, 14.19. Found: C, 67.33; H, 7.88; N, 7.29; 
Cl, 14.47. 
4.1 .4 .  3-Chloro-6 ,7 ,10 ,11 -tetrahydro -9-methyl -12-
12-[(6-chloro-1 ,2 ,3 ,4 -tetrahydroacr id in -9 -
yl )amino]dodecylamino -7 ,11 -
methanocyclooc ta[ b ]quinol ine (4g)  
It was prepared as described for 3g. Starting from huprine 1 
(290 mg, 1.02 mmol, 1 eq), and a solution of of 
bromoalkyltacrine 14g (587 mg, 1.22 mmol, 1.2 eq) in anhydrous 
DMSO (6 mL), a brown oily residue (1.20 g) was obtained and 
subjected to column chromatography purification (40–60 µm 
silica gel, CH2Cl2/50% aq. NH4OH 100:0.2), to afford the 
heterodimer 4g (311 mg, 45% yield) as a yellow oil; Rf 0.67 
(CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of 4g (122 mg, 0.18 mmol) in CH2Cl2 (6 mL) was 
filtered through a 0.2 m NYL filter, and treated with an excess 
of a methanolic solution of HCl (1.45 N, 1.1 mL, 1.59 mmol) and 
the resulting solution was concentrated in vacuo to dryness. The 
solid was taken in MeOH (0.5 mL) and precipitated upon 
addition of AcOEt (3 mL). The precipitated solid was separated, 
washed with pentane (32), and dried under standard conditions, 
to give 4g·2HCl (49 mg) as a yellow solid: mp 178–181 ºC; IR 
(KBr) ν 3500–2500 (max at 3224, 3034, 2924, 2854 and 2786, 
N
+
–H, N–H, and C–H st), 1632, 1583, 1572 and 1519 (Ar–C–C, 
Ar–C–N st) cm
–1
; 
1
H NMR (400 MHz, CD3OD) δ 1.27–1.44 
(complex signal, 16H, 3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2, 8’-H2, 
9’-H2, 10’-H2), 1.58 (s, 3H, 9-CH3), 1.79–1.95 (complex signal, 
10H, 10-Hendo, 13-Hsyn, 2’-H2, 11’-H2, 2”-H2, 3”-H2), 2.08 (br dm, 
J = 12.4 Hz, 1H, 13-Hanti), 2.55 (br dd, J = 17.2 Hz, J’ = 4.4, 1H, 
10-Hexo), 2.67 (br m, 2H, 1”-H2), 2.77 (br m, 1H, 7-H), 2.87 (d, J 
= 18.0 Hz, 1H, 6-Hendo), 3.00 (br m, 2H, 4”-H2), 3.20 (dd, J = 
18.0 Hz, J’ = 5.6 Hz, 1H, 6-Hexo), 3.45 (br m, 1H, 11-H), 3.96 (m, 
4H, 1’-H2,12’-H2), 4.85 (s, NH, NH
+
), 5.58 (br d, J = 4.4 Hz, 1H, 
8-H), 7.55 (d, J = 9.6 Hz, 1 H, 2-H, 7”-H), 7.79 (d, J = 3.6 Hz, 
1H, 4-H, 5”-H), 8.38 (dd, J = 9.0 Hz, J’ = 4.2 Hz, 2 H, 1-H, 8”-
H); 
13
C NMR (100.6 MHz, CD3OD) δ 21.8 (CH2, C3”), 22.8 
(CH2, C2”), 23.5 (CH3, 9-CH3), 24.5 (CH2, C1”), 24.7 (CH), 27.3 
(CH, C11), 27.7 (CH), 27.79 (CH2) and 27.81 (CH) (C7, C3’, 
C10’), 28.4 (CH2), 29.3 (CH2) (2 CH2, C13, C4”), 30.2 (2 CH2), 
30.58 (2 CH2) and 30.60 (2 CH2) (C4’, C5’, C6’, C7’, C8’, C9’), 
31.2 (CH2) and 31.3 (CH2) (C2’, C11’), 36.0 (CH2, C10), 36.1 
(CH2, C6), 49.1 (CH2) and 49.6 (CH2) (C1’, C12’), 113.3 (C), 
115.4 (C), 115.6 (C) and 117.6 (C) (C11a, C12a, C8a” and 
C9a”), 119.2 (CH) (C4, C5”), 125.1 (CH, C8), 126.6 (CH) and 
126.7 (CH) (C2, C7”), 128.7 (CH) and 129.4 (CH) (C1, C8”), 
134.5 (CH, C9), 140.1 (C) and 140.2 (C) (C3, C6”) 140.5 (C) and 
141.0 (C) (C4a, C10a”), 151.2 (C) and 152.1 (C) (C5a, C4a”), 
156.9 (C), 157.8 (C) (C12, C9”); HRMS (ESI), calcd for 
[C42H52
35
Cl2N4 + H
 +
] 638.3641, found 683.3622; Anal. calcd. for 
C42H52Cl2N4·2HCl·1.5H2O: C, 64.37; H, 7.33; N, 7.15; Cl, 18.09. 
Found: C, 64.04; H, 7.08; N, 6.81; Cl, 17.71. 
4.1 .5 .  6,7 ,10 ,11-Tetrahydro -9-methyl -12-10-
[(1 ,2 ,3 ,4 -tetrahydroacrid in -9 -
yl )amino]decylamino -7 ,11-
methanocyclooc ta[ b ]quinol ine (16f)  
It was prepared as described for 3g. Starting from huprine 15 
(250 mg, 1.00 mmol, 1 eq), and a solution of of 
bromoalkyltacrine 13f (551 mg, 1.32 mmol, 1.3 eq) in anhydrous 
DMSO (6 mL), a brown oily residue (1.04 g) was obtained and 
subjected to column chromatography purification (40–60 µm 
silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient 
elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 
100:0:0.2 to 95:5:0.2, the heterodimer 16f (518 mg, 88% yield) 
was isolated as a yellow oil; Rf 0.44 (CH2Cl2/MeOH/50% aq. 
NH4OH 9:1:0.05). 
A solution of 16f (518 mg, 0.88 mmol) in CH2Cl2 (25 mL) 
was filtered through a 0.2 m NYL filter, and treated with an 
excess of a methanolic solution of HCl (1.70 N, 4.65 mL, 7.90 
mmol) and the resulting solution was concentrated in vacuo to 
dryness. The solid was taken in MeOH (1.5 mL) and precipitated 
upon addition of AcOEt (11 mL). The precipitated solid was 
separated, washed with pentane (32), and dried under standard 
conditions, to give 16f·2HCl (481 mg) as a yellow solid: mp 
168–170 ºC; IR (KBr) ν 3500–2500 (max at 3380, 3237, 3120, 
3055, 3013, 2925, 2852, 2805, 2722 and 2663, N
+
–H, N–H, and 
C–H st), 1633, 1585 and 1522 (Ar–C–C, Ar–C–N st) cm
–1
; 
1
H 
NMR (400 MHz, CD3OD) δ 1.27–1.44 (complex signal, 12H, 3’-
H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2, 8’-H2), 1.57 (s, 3H, 9-CH3), 1.79–
1.96 (complex signal, 10H, 10-Hendo, 13-Hsyn, 2’-H2, 9’-H2, 2”-H2, 
3”-H2), 2.08 (dm, J = 12.4 Hz, 1H, 13-Hanti), 2.55 (br dd, J = 17.1 
Hz, J’ = 3.5 Hz, 1H, 10-Hexo), 2.70 (m, 1H, 1”-H2), 2.77 (br m, 
1H, 7-H), 2.90 (d, J = 18.0 Hz, 1H, 6-Hendo), 3.02 (m, 2H, 4”-H2), 
3.21 (dd, J = 18.0 Hz, J’ = 5.6 Hz, 1H, 6-Hexo), 3.47 (br m, 1H, 
11-H), 3.97 (complex signal, 4H, 1’-H2, 10’-H2), 4.85 (s, NH, 
NH
+
), 5.58 (br d, J = 4.4 Hz, 1H, 8-H), 7.57 (t, J = 6 Hz, 2H, 4-
H, 5”-H), 7.78 (t, J’ = 7.0 Hz, 2H) and 7.84 (t, J’ = 7.0 Hz, 2H) 
(2-H, 3-H, 6”-H, 7”-H), 8.39 (dd , J = 8.6 Hz, J’ = 3.8 Hz, 2 H, 1-
H, 8”-H); 
13
C NMR (100.6 MHz, CD3OD) δ 21.9 (CH2, C3”), 
23.0 (CH2, C2”), 23.5 (CH3, 9-CH3), 24.9 (CH2, C1”), 27.3 (CH, 
C11), 27.7 (CH), 27.8 (CH2) and 27.9 (CH) (C7, C3’, C8’), 29.3 
(CH2, C13), 29.4 (CH2, C4”), 30.26 (CH2), 30.29 (CH2), 30.48 
(CH2) and 30.53 (CH2) (C4’, C5’, C6’, C7’), 31.4 (CH2) and 31.5 
(CH2) (C2’, C9’), 36.0 (CH2) and 36.3 (CH2) (C6, C10), 49.1 
(CH2) and 49.6 (CH2) (C1’, C10’), 112.8 (C), 117.0 (C), 117.15 
(C) and 117.21 (C) (C11a, C12a, C8a”, C9a”), 120.1 (CH) and 
125.2 (CH) (C4, C5”), 126.1 (CH) and 126.3 (CH) (C8, C7”), 
126.5 (CH, C8”), 127.3 (CH), 134.1 (CH), 134.2 (CH), 134.5 
(C), 139.8 (C) and 140.2 (C) (C1, C2, C3, C4a, C9, C6”, C10a”), 
150.7 (C) and 151.6 (C) (C5a, C4a”), 157.0 (C) and 158.0 (C) 
(C12, C9”); HRMS (ESI), calcd for [C40H50N4 + H
 +
] 587.4108, 
found 587.4099; Anal. calcd. for C40H50N4·2HCl·2H2O: C, 69.05; 
H, 8.11; N, 8.05; Cl, 10.19. Found: C, 68.68; H, 8.08; N, 7.76; 
Cl, 10.18.                      
4.1 .6 .  6,7 ,10 ,11-Tetrahydro -9-methyl -12-12-
[(1 ,2 ,3 ,4 -tetrahydroacrid in-9 -
yl )amino]dodecylamino -7 ,11 -
methanocyclooc ta[ b ]quinol ine (16g)  
It was prepared as described for 3g. Starting from huprine 15 
(300 mg, 1.20 mmol, 1 eq), and a solution of of 
bromoalkyltacrine 13g (642 mg, 1.44 mmol, 1.2 eq) in anhydrous 
DMSO (6.5 mL), a brown oily residue (805 mg) was obtained 
and subjected to column chromatography purification (40–60 µm 
silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient 
elution. On elution with CH2Cl2/MeOH/50% aq. NH4OH 
99:1:0.2, the heterodimer 16g (609 mg, 83% yield) was isolated 
as a yellow oil; Rf 0.53 (CH2Cl2/MeOH/50% aq. NH4OH 
9:1:0.05). 
A solution of 16g (609 mg, 0.99 mmol) in CH2Cl2 (33 mL) 
was filtered through a 0.2 m NYL filter, and treated with an 
excess of a methanolic solution of HCl (1.45 N, 6.2 mL, 8.99 
mmol) and the resulting solution was concentrated in vacuo to 
dryness. The solid was taken in MeOH (2 mL) and precipitated 
upon addition of AcOEt (14 mL). The precipitated solid was 
separated, washed with pentane (32), and dried under standard 
conditions, to give 16g·2HCl (612 mg) as a yellow solid: mp 
159–162 ºC; IR (KBr) ν 3500–2500 (max at 3386, 3236, 3114, 
3054, 3007, 2923, 2851, 2800, 2722 and 2663, N
+
–H, N–H, and 
C–H st), 1633, 1585, 1568 and 1520 (Ar–C–C, Ar–C–N st) cm
–1
; 
1
H NMR (400 MHz, CD3OD) δ 1.28–1.46 (complex signal, 16H, 
3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2, 8’-H2, 9’-H2, 10’-H2), 1.58 (s, 
3H, 9-CH3), 1.79-1.97 (complex signal, 10H, 10-Hendo, 13-Hsyn, 
2’-H2, 11’-H2, 2”-H2 and 3”-H2), 2.09 (dm, J = 11.0 Hz, 1H, 13-
Hanti), 2.56 (br dd, J = 17.6 Hz, J’ = 4.4 Hz, 1H, 10-Hexo), 2.71 
(m, 1H, 1”-H2), 2.77 (br m, 1H, 7-H), 2.90 (d, J = 18.0 Hz, 1H, 6-
Hendo), 3.02 (m, 2H, 4”-H2), 3.21 (dd, J = 17.8 Hz, J’ = 5.4 Hz, 
1H, 6-Hexo), 3.48 (br m, 1H, 11-H), 3.95 (t, J = 7.8 Hz, 2H) and 
4.00 (td, J = 10.4 Hz, J’ = 7.2 Hz, J” = 3.4 Hz, 2H) (1’-H2, 12’-
H2), 4.85 (s, NH, NH
+
), 5.58 (br d, J = 4.4 Hz, 1H, 8-H), 7.57 
(tdd, J = 7.6 Hz, J’ = 2.8 Hz, J” = 1.3 Hz, 2 H, 4-H, 5”-H), 7.78 
(t, J = 7.6 Hz, 2H) and 7.84 (t, J = 7.6 Hz, 2H) (2-H, 3-H, 6”-H 
and 7”-H), 8.40 (dd , J = 8.6 Hz, J’ = 4.2 Hz, 2 H, 1-H, 8”-H); 
13
C NMR (100.6 MHz, CD3OD) δ 21.9 (CH2, C3”), 23.0 (CH2, 
C2”), 23.5 (CH3, 9-CH3), 24.9 (CH2, C1”), 27.3 (CH, C11), 27.7 
(CH), 27.8 (CH2), 27.9 (CH) (C7, C3’, C10’), 29.3 (CH2, C13), 
29.4 (CH2, C4”), 30.3 (CH2), 30.59 (3 CH2) and 30.62 (2 CH2) 
(C4’, C5’, C6’, C7’, C8’, C9’), 31.4 (CH2) and 31.5 (CH2) (C2’, 
C11’), 36.0 (CH2) and 36.3 (CH2) (C6, C10), 49.1 (CH2) and 49.6 
(CH2) (C1’, C12’), 112.8 (C), 117.0 (C), 117.15 (C) and 117.21 
(C) (C11a, C12a, C8a” and C9a”), 120.1 (CH) and 125.2 (CH) 
(C4 and C5”), 126.1 (CH) and 126.3 (CH) (C8, C7”), 126.5 (CH, 
C8”), 127.3 (CH), 134.1 (CH), 134.2 (CH), 134.5 (C), 139.8 (C) 
and 140.3 (C) (C1, C2, C3, C4a, C9, C6”, C10a”), 150.7 (C) and 
151.6 (C) (C5a, C4a”), 157.0 (C) and 158.0 (C) (C12, C9”); 
HRMS (ESI), calcd for [C42H54N4 + H
 +
] 615.4421, found 
615.4423; Anal. calcd. for C42H54N4·2HCl·2H2O: C, 69.69; H, 
8.35; N, 7.74; Cl, 9.80. Found: C, 69.75; H, 8.40; N, 7.49; Cl, 
9.62. 
4.1 .7 .  6,7 ,10 ,11-Tetrahydro -9-methyl -12-10-[ (6 -
chloro -1 ,2 ,3 ,4 -te trahydroacrid in -9 -
yl )amino]decylamino -7 ,11-
methanocyclooc ta[ b ]quinol ine (17f)  
It was prepared as described for 3g. Starting from huprine 15 
(274 mg, 1.10 mmol, 1 eq), and a solution of of 
bromoalkyltacrine 14f (596 mg, 1.32 mmol, 1.3 eq) in anhydrous 
DMSO (6 mL), a brown oily residue (810 mg) was obtained and 
subjected to column chromatography purification (40–60 µm 
silica gel, EtOAc/hexane/Et3N mixtures, gradient elution). On 
elution with EtOAc/hexane/Et3N 50:50:0.2 to 100:0:0.2, the 
heterodimer 17f (477 mg, 70% yield) was isolated as a yellow 
oil; Rf 0.51 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of 17f (450 mg, 0.72 mmol) in CH2Cl2 (48 mL) 
was filtered through a 0.2 m NYL filter, and treated with an 
excess of a methanolic solution of HCl (0.75 N, 9.0 mL, 6.75 
mmol) and the resulting solution was concentrated in vacuo to 
dryness. The solid was taken in MeOH (1.5 mL) and precipitated 
upon addition of AcOEt (10 mL). The precipitated solid was 
separated, washed with pentane (32), and dried under standard 
conditions, to give 17f·2HCl (351 mg) as a yellow solid: mp 
176–178 ºC; IR (KBr) ν 3500–2500 (max at 3351, 3232, 3114, 
3048, 3001, 2924, 2852, 2270, 2792, and 2651, N
+
–H, N–H, and 
C–H st), 1632, 1585, 1571 and 1519 (Ar–C–C, Ar–C–N st) cm
–1
; 
1
H NMR (400 MHz, CD3OD) δ 1.32–1.44 (complex signal, 12H, 
3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2, 8’-H2), 1.57 (s, 3H, 9-CH3), 
1.80–1.96 (complex signal, 10H, 10-Hendo, 13-Hsyn, 2’-H2, 9’-H2, 
2”-H2, 3”-H2), 2.08 (dm, J = 12.4 Hz, 1H, 13-Hanti), 2.56 (br dd, J 
= 16.4 Hz, 1H, 10-Hexo), 2.68 (m, 2H, 1”-H2), 2.77 (br m, 1H, 7-
H), 2.91 (d, J = 18.0 Hz, 1H, 6-Hendo), 3.01 (m, 2H, 4”-H2), 3.21 
(dd, J = 17.8 Hz, J’ = 5.0 Hz, 1H, 6-Hexo), 3.48 (br m, 1H, 11-H), 
3.93 (t, J = 6.8 Hz, 2H) and 3.99 (t, J = 6.8 Hz, 2H) (1’-H2, 10’-
H2), 4.85 (s, NH, NH
+
), 5.58 (br d, J = 4.4 Hz, 1H, 8-H), 7.53–
7.58 (complex signal, 2 H, 4-H, 7”-H), 7.80 (s, 1H, 5”-H), 
superimposed in part 7.79 (t, J = 8.0 Hz) and 7.83 (t, J = 8.0 Hz) 
(2-H, 3-H), 8.38 (dd, J = 8.0 Hz, J’ = 5.2 Hz, 2 H, 1-H, 8”-H); 
13
C NMR (100.6 MHz, CD3OD) δ 21.8 (CH2, C3”), 22.9 (CH2, 
C2”), 23.5 (CH3, 9-CH3), 24.8 (CH2, C1”), 27.3 (CH, C11), 27.7 
(CH2), 27.8 (CH2) and 27.9 (CH) (C7, C3’, C8’), 29.3 (CH2), 
29.4 (CH2) (C13, C4”), 30.3 (2 CH2), 30.46 (CH2) and 30.51 
(CH2) (C4’, C5’, C6’, C7’), 31.35 (CH2) and 31.41 (CH2) (C2’, 
C9’), 36.0 (CH2, C10), 36.3 (CH2, C6), 49.2 (CH2) and 49.6 
(CH2) (C1’, C10’), 113.3 (C), 115.4 (C), 117.1 (C) and 117.2 (C) 
(C11a, C12a, C8a”, C9a”), 119.1 (CH) and 120.1 (C), (C4, C5”), 
125.2 (CH, C8), 126.1 (CH) and 126.7 (CH) (C2, C7”), 127.3 
(CH) and 128.8 (CH) (C1, C8”), 134.2 (CH), 134.5 (C), 140.0 
(C), 140.2 (C) and 140.5 (C) (C3, C4a, C9, C6”, C10a”), 150.7 
(C) and 152.1 (C) (C5a, C4a”), 157.0 (C) and 157.8 (C) (C12, 
C9”); HRMS (ESI), calcd for [C40H49
35
ClN4 + H
 +
] 621.3719, 
found 621.3717; Anal. calcd. for C40H49ClN4·2HCl·2H2O: C, 
65.79; H, 7.59; N, 7.67; Cl, 14.56. Found: C, 66.10; H, 7.35; N, 
7.56; Cl, 14.59. 
4.1 .8 .  6,7 ,10 ,11-Tetrahydro -9-methyl -12-12-[ (6 -
chloro -1 ,2 ,3 ,4 -te trahydroacrid in -9 -
yl )amino]dodecylamino -7 ,11 -
methanocyclooc ta[ b ]quinol ine (17g)  
It was prepared as described for 3g. Starting from huprine 15 
(278 mg, 1.11 mmol, 1 eq), and a solution of of 
bromoalkyltacrine 14g (639 mg, 1.33 mmol, 1.2 eq) in anhydrous 
DMSO (6 mL), a brown oily residue (1.30 g) was obtained and 
subjected to column chromatography purification (40–60 µm 
silica gel, CH2Cl2/50% aq. NH4OH 100:0.2), to afford the 
heterodimer 17g (449 mg, 62% yield) as a yellow oil; Rf 0.58 
(CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of 17g (143 mg, 0.22 mmol) in CH2Cl2 (7 mL) was 
filtered through a 0.2 m NYL filter, and treated with an excess 
of a methanolic solution of HCl (1.45 N, 1.35 mL, 2.00 mmol) 
and the resulting solution was concentrated in vacuo to dryness. 
The resulting solid was washed with pentane (32), and dried 
under standard conditions, to give 17g·2HCl (121 mg) as a 
yellow solid: mp 182–185 ºC; IR (KBr) ν 3500–2500 (max at 
3366, 3240, 3050, 2922, 2852 and 2796, N
+
–H, N–H, and C–H 
st), 1631, 1584, 1572 and 1519 (Ar–C–C, Ar–C–N st) cm
–1
; 
1
H 
NMR (400 MHz, CD3OD) δ 1.29–1.45 (complex signal, 16H, 3’-
H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2, 8’-H2, 9’-H2, 10’-H2), 1.58 (s, 3H, 
9-CH3), 1.82–1.97 (complex signal, 10H, 10-Hendo, 13-Hsyn, 2’-
H2, 11’-H2, 2”-H2, 3”-H2), 2.09 (dm, J = 13.2 Hz, 1H, 13-Hanti), 
2.56 (br dd, J = 15.6 Hz, 1H, 10-Hexo), 2.68 (m, 2H, 1”-H2), 2.78 
(br m, 1H, 7-H), 2.89 (d, J = 17.6 Hz, 1H, 6-Hendo), 3.00 (m, 2H, 
4”-H2), 3.21 (dd, J = 17.8 Hz, J’ = 5.0 Hz, 1H, 6-Hexo), 3.47 (br 
m, 1H, 11-H), 3.95 (t, J = 6.2 Hz, 2H), 4.00 (br t, 2H) (1’-H2, 
12’-H2), 4.85 (s, NH, NH
+
), 5.59 (br d, J = 3.6 Hz, 1H, 8-H), 7.57 
(complex signal, 2H, 4-H, 5”-H), 7.79 (s, 1H, 5”-H), 
superimposed in part 7.77 (t, J = 7.6 Hz) and 7.84 (t, J = 7.6 Hz) 
(2-H, 3-H), 8.40 (t, J = 7.6 Hz, 2H, 1-H, 8”-H); 
13
C NMR (100.6 
MHz, CD3OD) δ 21.8 (CH2, C3”), 22.9 (CH2, C2”), 23.5 (CH3, 9-
CH3), 24.5 (CH2, C1”), 24.8 (CH2), 27.3 (CH, C11), 27.7 (CH2), 
27.88 (CH2) and 27.93 (CH) (C7, C3’, C10’), 29.35 (CH2) and 
29.44 (CH2) (C13, C4”), 30.3 (2 CH2) and 30.7 (4 CH2) (C4’, 
C5’, C6’, C7’, C8’, C9’), 31.4 (CH2) and 31.5 (CH2) (C2’, C10’), 
36.0 (CH2, C10), 36.3 (CH2, C6) 49.3 (CH2) and 49.7 (CH2) (C1’, 
C12’), 113.3 (C), 115.5 (C), 117.17 (C) and 117.25 (C) (C11a, 
C12a, C8a” and C9a”), 119.2 (CH) and 120.1 (C) (C4, C5”), 
125.2 (CH, C8), 126.2 (CH) and 126.8 (CH) (C2, C7”), 127.3 
(CH) and 128.8 (CH) (C1, C8''), 134.2 (CH), 134.6 (C), 140.1 
(C), 140.3 (C) and 140.6 (C) (C3, C4a, C9 and C6”, C10a”), 
150.7 (C) and 152.1 (C) (C5a, C4a”), 157.1 (C) and 157.9 (C) 
(C12, C9”); HRMS (ESI), calcd for [C42H53
35
ClN4 + H
 +
] 
649.4032, found 649.4022; Anal. calcd. for 
C42H53ClN4·2HCl·2H2O: C, 66.52; H, 7.84; N, 7.39; Cl, 14.03. 
Found: C, 66.95; H, 7.99; N, 6.97; Cl, 13.83. 
 Biological profiling 
4.1 .9 .  T.  bruce i  cul tur ing  and evaluat ion  of  
trypanocidal  act iv i t y  
Bloodstream form T. brucei (strain 221) were cultured at 37 
ºC in modified Iscove’s medium.
59
 Trypanocidal activity was 
assessed by growing parasites in the presence of various 
concentrations of the 4-aminoquinoline-based heterodimeric 
compounds and determining the levels which inhibited growth by 
50% (IC50) and 90% (IC90). T. brucei in the logarithmic phase of 
growth were diluted back to 0.25  105 mL
1
 and aliquoted into 
96-well plates. Heterodimeric compounds were then added at a 
range of concentrations and the plates incubated at 37 °C. Each 
drug concentration was tested in triplicate. Resazurin was added 
after 48 h and the plates incubated for a further 16 h and the 
plates then read in a Spectramax plate reader. Results were 
analysed using GraphPad Prism. 
4.1 .10 .  P.  fa lc iparum  cul turing and eva luat ion o f  
ant ip lasmodial  act iv i ty  
Malaria parasites were maintained in human A
+
 erythrocytes 
suspended in RPMI 1640 medium supplemented with A
+
 serum 
and D-glucose according to previously published methods.
60,61
 
Cultures containing predominantly early ring stages were used 
for testing. Compounds were dissolved in DMSO and further 
diluted with RPMI 1640 medium (the final DMSO concentration 
did not exceed 0.5% which did not affect parasite growth). Two-
fold serial dilutions were made in 96-well microtitre plates in 
duplicate and infected erythrocytes were added to give a final 
volume of 100 μL with haematocrit 2.5% and 1% parasitaemia. 
Chloroquine diphosphate was used as a positive control and 
uninfected and infected erythrocytes without compounds were 
included in each test. Plates were placed into a modular incubator 
gassed with nitrogen 93%, oxygen 3%, carbon dioxide 4% and 
incubated at 37 ºC for 48 h. Parasite growth was assessed by 
measuring lactate dehydrogenase activity.
62
 The reagent used 
contained the following in each mL: acetylpyridine adenine 
dinucleotide (APAD), 0.74 mg; lithium lactate, 19.2 mg; 
diaphorase, 0.1 mg; triton X-100, 2 μL; and nitroblue 
tetrazolium, 1 mg.  Fifty μL of this reagent was added to each 
well and mixed, and plates were incubated for 1015 min at 37 
ºC. Absorbances were read at 550 nm using a Dynatech 
Laboratories MRX microplate reader and % inhibition of growth 
was calculated by comparison with control values. IC50 values 
were determined using linear regression analysis (Microsoft 
Excel). 
4.1 .11 .  Cytotoxic  ac t iv i t y  agains t  ra t  skele ta l  
myoblast  L6 cel l s  
Cytotoxicity against mammalian cells was assessed using 
microtitre plates following a described procedure.
63 
Briefly, L6 
cells (a rat skeletal muscle line) were seeded at 1  10
4 
mL
1
 in 
200 µL of growth medium containing different compound 
concentrations. The plates were incubated for 6 days at 37 
º
C and 
20 µL resazurin was then added to each well. After a further 8 h 
incubation, the fluorescence was determined using a Spectramax 
plate reader. 
4.1 .12 .  Acetylchol inesterase  inhibi tory  ac t iv i ty  
The inhibitory activities of the novel 4-aminoquinoline-based 
heterodimeric compounds 3g, 4g, 16f-g, and 17f-g against human 
recombinant AChE (Sigma-Aldrich) were evaluated 
spectrophotometrically by the method of Ellman et al.
43
 The 
reactions took place in a final volume of 300 L of 0.1 M 
phosphate-buffered solution pH 8.0, containing hAChE (0.02 
u/mL) and 333 M 5,5'-dithiobis(2-nitrobenzoic) acid (DTNB; 
Sigma-Aldrich) solution used to produce the yellow anion of 5-
thio-2-nitrobenzoic acid. Inhibition curves were performed in 
duplicates using at least 10 increasing concentrations of 
inhibitors and preincubated for 20 min at 37 ºC before adding the 
substrate. One duplicate sample without inhibitor was always 
present to yield 100% of AChE activity. Then, substrate 
acetylthiocholine iodide (450 M; Sigma-Aldrich) was added 
and the reaction was developed for 5 min at 37 ºC. The colour 
production was measured at 414 nm using a labsystems 
Multiskan spectrophotometer.  
Data from concentrationinhibition experiments of the 
compounds were calculated by non-linear regression analysis, 
using the GraphPad Prism program package (GraphPad 
Software; San Diego, USA), which gave estimates of the IC50 
(concentration of drug producing 50% of enzyme activity 
inhibition). Results are expressed as mean  S.E.M. of at least 4 
experiments performed in duplicate. 
4.1 .13 .  Determinat ion  of  bra in permeabi l i t y:  
PAMPA-BBB assay  
The in vitro permeability (Pe) of the novel 4-aminoquinoline-
based heterodimeric compounds 3g, 4g, 16f-g, and 17f-g and 
fourteen known drugs through lipid extract of porcine brain 
membrane was determined by using a parallel artificial 
membrane permeation assay,
44
 using a mixture PBS:EtOH 70:30. 
Assay validation was made by comparison of the experimental Pe 
values of the known drugs with their reported values, which 
showed a good correlation: Pe (exp) = 1.4974 Pe (lit) – 0.8434 
(R
2 
= 0.9428). From this equation and the limits established by Di 
et al. for BBB permeation,
44
 three ranges of permeability were 
established: compounds of high BBB permeation  (CNS+): Pe 
(10
6
 cm s
1
) > 5.10; compounds of low BBB permeation (CNS–
): Pe (10
6
 cm s
1
) < 2.15; and  compounds of uncertain BBB 
permeation (CNS+/–): 5.10 > Pe (10
6
 cm s
1
) > 2.15. 
 
Table 4 
Reported and experimental permeability values (Pe 10
–6
 cm s
–
1
) of 14 commercial drugs used for the PAMPA-BBB assay 
validation 
Compound  Literature valuea Experimental valueb  
Cimetidine 0.0 0.70 ± 0.03 
Lomefloxacin 1.1 0.75 ± 0.02 
Norfloxacin 0.1 0.90 ± 0.02 
Ofloxacin 0.8 0.97 ± 0.01 
Hydrocortisone 1.9 1.40 ± 0.05 
Piroxicam 2.5 1.71 ± 0.02 
Clonidine 5.3 6.50 ± 0.05 
Corticosterone 5.1 6.70 ± 0.10 
Imipramine 13 12.3 ± 0.10 
Promazine 8.8 13.8 ± 0.30 
Progesterone 9.3 16.8 ± 0.30 
Desipramine 12 17.8 ± 0.10 
Testosterone 17 24.0 ± 0.14 
Verapamil 16 25.3 ± 0.78 
a Taken from ref. 44. 
b Values are expressed as the mean ± SD of three independent experiments. 
 
4.1 .14 .  Trypanothione reductase  inhibi tory act iv i ty  
The TryR inhibitory activity of selected compounds was 
determined through a described methodology based on the 
colorimetric reduction of DTNB by dithiol trypanothione 
(T[SH]2).
53,54
 The assay mixture consisted of: 40 mM HEPES pH 
7.4, 1 mM EDTA, 6 µM trypanothione disulfide (T[S]2), 50 µM 
DTNB, 2 mU mL
1
 TryR and 150 µM NADPH. IC50 values were 
determined using 11 serial dilutions. Starting with 12 µL of a 10 
mM DMSO solution of each compound, 6 µL was removed and 
added to another Eppendorf tube containing 6 µL of DMSO. The 
tube was sealed, mixed and then briefly centrifuged to ensure that 
the sample was a the bottom of the tube. This procedure was 
repeated 11 times to produce 12 serial 50% dilutions. Assays 
were performed in triplicate, by adding 158.2 mL of reagents 
(TryR + trypanothione + DTNB in assay buffer) to 1.8 µL of the 
inhibitor solution, and finally 20 µL of NADPH solution to start 
the assay. Absorbance at 412 nm was monitored at 25 ºC for 15 
min using a SpectraMax 340PC (Molecular Devices) plate 
reader. Data were inspected for linearity and IC50 values 
determined by nonlinear regression to the following four-
paramenter equation: y = (range/(1+x/IC50)
Slope factor
) + 
background. The choice of disulphide concentration represents 
[S] ≈ Km. 
4.1 .15 .  β -Haematin inhib i tory  act iv i t y  
The quantitative β-haematin inhibitory activity (BHIA) assay 
is based on the differential solubility of haemin and β-haematin 
in DMSO (haemin is soluble while β-haematin is insoluble).
57,58
 
The method determines a 50% inhibitory concentration for β-
haematin inhibition in equivalents of the compound under test 
with respect to haemin (BHIA50). Drug samples were dissolved in 
DMSO (25%) to give concentrations of 32 mM. Fifty μL aliquots 
of DMSO (25%) were placed in wells of 96-well microplates and 
serial dilutions of drugs were made to give concentrations of 0.5–
32 mM. Fifty μL haemin chloride  (8 mM) in DMSO was then 
added to each well. Drug free controls were prepared by adding 
haemin chloride solution (50 μL) to 50 μL DMSO (25%) in place 
of drug solution; chloroquine diphosphate and tetracycline 
hydrochloride were used as positive and negative controls 
respectively. β-haematin formation was initiated by the addition 
of 100 μL of 8 M acetate buffer (pH 5.0) and the plates were then 
incubated at 37 ºC for 18 h. 
Following incubation, microplates were inspected visually. In 
wells where β-haematin formation was strongly inhibited clumps 
of black precipitate consisting of drug-haem complex were 
observed with a clear supernatant whereas less or no inhibition 
was indicated by wells with a precipitate evenly distributed 
throughout. The minimum inhibitory concentration was taken to 
be the lowest concentration of drug that was see to produce 
clumps of precipitate. The quantitative estimation of β-haematin 
formation using methodology similar to that reported by Basilico 
et al.,
57
 was carried out as follows. Samples were transferred to 
Eppendorf tubes, centrifuged and the supernatants discarded. 
DMSO (200 μL) was used to wash out any remaining precipitate 
from the microplate wells and then thoroughly mixed with the 
precipitate in the Eppendorf tubes. After centrifuging again, the 
supernatants were discarded. Insoluble β-haematin was then 
dissolved by adding 200 μL 0.1M NaOH and mixing thoroughly.  
Aliquots of 75 μL were transferred to a fresh microplate and 
optical densities read at 400 nm using a Dynatech Laboratories 
MRX microplate reader and percent inhibition of β-haematin 
compared to drug-free controls calculated using linear regression 
analysis. A minimum of three separate determinations was 
carried out for each compound except for inactive compounds in 
which two determinations were carried out. 
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